Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

BACKGROUND: The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis. The primary and planned 3-year analyses of COMFORT-I data demonstrated that ruxolitinib—the first myelofibrosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstovsek, Srdan, Mesa, Ruben A., Gotlib, Jason, Gupta, Vikas, DiPersio, John F., Catalano, John V., Deininger, Michael W. N., Miller, Carole B., Silver, Richard T., Talpaz, Moshe, Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O., Hexner, Elizabeth O., Lyons, Roger M., Paquette, Ronald, Raza, Azra, Jones, Mark, Kornacki, Deanna, Sun, Kang, Kantarjian, Hagop
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322633/
https://www.ncbi.nlm.nih.gov/pubmed/28228106
http://dx.doi.org/10.1186/s13045-017-0417-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322633/
https://www.ncbi.nlm.nih.gov/pubmed/28228106
http://dx.doi.org/10.1186/s13045-017-0417-z

Ejemplares similares